VYNE Therapeutics Inc.

NasdaqCM:VYNE Stock Report

Market Cap: US$22.7m

VYNE Therapeutics Future Growth

Future criteria checks 0/6

VYNE Therapeutics's earnings are forecast to decline at 10.5% per annum while its annual revenue is expected to grow at 77.7% per year.

Key information

-10.5%

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate77.7%
Future return on equityn/a
Analyst coverage

Low

Last updated18 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Jun 27

We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 09

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 27

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 04

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 12

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics press release (NASDAQ:VYNE): Q2 Non-GAAP EPS of -$0.13 beats by $0.02. Revenue of $0.13M (-55.2% Y/Y) beats by $0.03M. As of June 30, 2022, VYNE had cash and cash equivalents of $42.8 million. Shares -4% PM.
Analysis Article • Jul 02

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 19

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 13

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Sales of Vyne Therapeutic's minocycline products were just $4 million last quarter which may hamper the company’s ability to sell or license the franchise. Vyne has shifted its focus from marketing the approved minocycline products to 3 pre-clinical assets which require substantial cash and expose investors to a high degree of clinical risk. The largest institutional shareholder has sold most of their position. The cash position is sufficient only through Q2 of 2022 and significant dilution is likely.
Analysis Article • Dec 03

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Aug 13

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of VYNE Therapeutics Inc. ( NASDAQ:VYNE ) shareholders today, when the analysts...
Seeking Alpha • Jun 30

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

VYNE stock has depreciated by 65% in the last 3 months. There are no overwhelmingly critical factors behind this. The market, and smart money, just seem to dislike the stock.

Earnings and Revenue Growth Forecasts

NasdaqCM:VYNE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-115-121N/A1
12/31/2027N/A-75-81N/A1
12/31/2026N/A-50-56N/A1
3/31/20260-22-26-26N/A
12/31/20251-27-33-33N/A
9/30/20251-34-38-38N/A
6/30/20250-39-40-40N/A
3/31/20251-42-38-37N/A
12/31/20241-40-34-34N/A
9/30/20240-34-30-30N/A
6/30/20240-28-27-27N/A
3/31/20240-29-28-28N/A
12/31/20230-28-25-25N/A
9/30/20230-29-25-25N/A
6/30/20230-33-27-27N/A
3/31/20230-31-26-26N/A
12/31/20220-34-29-29N/A
9/30/20221-35-34-34N/A
6/30/20221-40-45-45N/A
3/31/20221-42-53-53N/A
12/31/20211-44-56-56N/A
9/30/20215-59-72-72N/A
6/30/20218-69-78-78N/A
3/31/202119-226-97-97N/A
12/31/202021-256-137-137N/A
9/30/202017-270-134-134N/A
6/30/202014-269-133-132N/A
3/31/20202-120-110-109N/A
12/31/20190-95N/A-73N/A
9/30/20191-71N/A-62N/A
6/30/20192-64N/A-62N/A
3/31/20193-63N/A-62N/A
12/31/20184-74N/A-69N/A
9/30/20184-77N/A-70N/A
6/30/20184-80N/A-69N/A
3/31/20184-77N/A-64N/A
12/31/20174-66N/A-53N/A
9/30/20174-59N/A-53N/A
6/30/20176-47N/A-36N/A
3/31/20176-39N/A-32N/A
12/31/20166-29N/A-27N/A
9/30/20164-24N/A-18N/A
6/30/20162-21N/A-19N/A
3/31/20161-18N/A-18N/A
12/31/20151-17N/A-12N/A
9/30/20154-11N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VYNE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VYNE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VYNE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VYNE is forecast to have no revenue next year.

High Growth Revenue: VYNE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VYNE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 09:37
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VYNE Therapeutics Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas TsaoBarclays
Jason Matthew GerberryBofA Global Research
Louise ChenGuggenheim Securities, LLC